White papers and peer-reviewed literature on TOL.

The foundational patent describing combined stimulation of voltage-gated sodium channels and pharmacological blockade of sodium pumps to induce selective osmotic lysis of cancer cells.

Original mechanism paper demonstrating selective lysis of breast carcinoma cells through simultaneous voltage-gated sodium channel stimulation and sodium pump blockade. PMID 29643996.

Preclinical demonstration of the TOL approach in highly invasive breast carcinoma models using pulsed magnetic field stimulation. PMID 32486340.

Comprehensive review of TOL as a novel approach to targeted cancer therapy, integrating mechanism, preclinical data, and translational considerations. PMID 35453588.

Conceptual paper framing cancer as a channelopathy and the implications of that framing for targeted therapy development. PMID 36230549.

FASEB Journal supplement abstract presenting Targeted Osmotic Lysis experimental data at Experimental Biology 2022.

Companion abstract to R5215, presenting additional Targeted Osmotic Lysis experimental data at Experimental Biology 2022.

FASEB Journal supplement abstract presenting earlier-stage Targeted Osmotic Lysis preclinical results.

Emergency-use TOL administration in a 46-year-old female with stage IIB cervical squamous cell carcinoma demonstrating tumor density reduction from 70 to 47 Hounsfield units on follow-up imaging. PMID 34201380.

A 51-year-old male presented with a stage 3 (pT3b) malignant melanoma of the left preauricular region, 2.1 mm tumor thickness, level IV invasion, ulcerated, with positive peripheral and deep biopsy margins. The patient was offered Moh's microsurgical resection with sentinel lymph node biopsy and declined. Immunohistochemical screening of the biopsy with a panspecific anti-VGSC antibody confirmed sufficient voltage-gated sodium channel expression to predict TOL response. Three weekly cycles of TOL were administered under IRB-approved pilot protocol GARM #12132023 at the GARM International Foundation Clinic in Roatan, Honduras. Oral digoxin 0.25 mg daily was loaded for seven days prior to arrival and continued through treatment, with a confirmed trough serum level of 0.9 mcg per L. The patient entered a custom-built coaxial ring pulsed-electric-field device (CPEFG, The Phantom Laboratory, Salem NY) for two hours of stimulation on two consecutive days per cycle (18 V per m, 10 ms square-wave pulses, 15 ms interstimulus interval). The published report describes complete resolution of the primary lesion without residual scarring, MRI of the brain, face and neck at five weeks post-treatment showing no evidence of residual or metastatic disease, and no treatment-related adverse events through six months of follow-up. The authors disclose that D. Paul, H.J. Gould III, and P.R. Miller are co-founders of Oleander Medical Technologies, Inc., which funded the research services contract.

Human case report documenting TOL treatment of a cutaneous squamous cell carcinoma patient. Adds skin carcinoma to the histology profile documented for this approach.

Case series of advanced carcinoma in companion animals (dogs and cats) treated with TOL, reporting 75 to 90 percent tumor necrosis on follow-up. PMID 35967596.

Structured safety study of TOL therapy in healthy Beagles, evaluating cardiovascular, hematologic, and clinical chemistry endpoints under formal veterinary clinical protocol. PMID 39681070.

Cited in the foundational FixCancer.org reference set as independent confirmation of the mechanism rationale.